The Pathologist

For patients with advanced non-small cell lung cancer (NSCLC), tissue samples are typically small biopsies. These samples undergo standard of care evaluation for >10 biomarkers to identify targeted, personalized therapies. If only single-gene tests are ordered, it is unlikely all biomarkers will be successfully tested. Furthermore, the patient may not be able to get a second biopsy for comprehensive testing. Ordering single-gene tests before comprehensive profiling creates longer wait times for results, which can be problematic for selecting optimal treatment.Join Drs. Kyle C. Strickland and Rebecca A. Previs from Labcorp Oncology’s Medical Affairs team for this webinar to hear about tissue stewardship from a pathologist and oncologist’s perspectives. We will review our latest data from advanced NSCLC which demonstrate that single-gene testing, if performed prior to comprehensive genomic profiling, doubles comprehensive genomic profiling failures due to tissue insufficiency and DNA extraction failures. We will share best practices to optimize tissue utilization and ensure patients with advanced NSCLC receive all recommended biomarker testing.Learning Objectives:• Describe the various tissue testing methodologies available for evaluation of biomarkers for patients with advanced NSCLC.• Compare biomarker testing paradigms with single gene testing and comprehensive genomic profiling to describe benefits and pitfalls of each strategy.• Integrate best practices for tissue stewardship to optimize biomarker testing in advanced NSCLC.Speakers: Kyle Strickland, MD, PhD (Labcorp Oncology, Director, Medical Affairs and Adjunct Associate Professor, Duke University Medical Center, Duke Cancer Institute, Department of Pathology, Labcorp), Rebecca Previs, MD, MS (Labcorp Oncology, Director, Medical Affairs and Adjunct Assistant Professor, Duke University Medical Center, Duke Cancer Institute, Department of Obstetrics & Gynecology, Division of Gynecologic Oncology, Labcorp).